# Dayan K. Gandhi, M.D. – FDA 483, Jul 2, 2026

Source: https://www.keypedia.com/records/483/dayan-k-gandhi-md/46972669-af29-424a-ac8f-8c4db4bf088f

> FDA 483 for Dayan K. Gandhi, M.D. on July 02, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Dayan K. Gandhi, M.D.
- Inspection Date: 2026-07-02
- Product Type: drugs
- Office Name: Los Angeles District Office
- Summary: An FDA inspection of Dayan K. Gandhi, M.D., a clinical investigator in Granada Hills, CA, revealed significant deviations from clinical trial protocols. The firm failed to administer investigational product according to the plan, improperly enrolled a subject, and did not ensure IP interruption when required. Additionally, the firm failed to promptly report two Serious Adverse Events to the study sponsor.

## Related Officers

- [Andra Lepnis](https://www.keypedia.com/people/andra-lepnis/38811302-3d96-427a-955d-c4c42de05a7c)
- [issuing_officer](https://www.keypedia.com/people/farwa-z-razvi/4ac4d0de-addf-4657-8756-0676015cea8a)

Company: https://www.keypedia.com/companies/dayan-k-gandhi-md/fb591ad3-bf38-4c06-8de1-07329562c8bf

Office: https://www.keypedia.com/offices/los-angeles-district-office/edcf1dfe-596a-43b8-8df4-07d9cd94763b